Showing results (251-260 of 365) with videos related to
Sort By:
Pageof 37
Breast Cancer Research : BCR|January 18, 2024
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancerJieun Park, Eun Sol Chang, Ji-Yeon Kim, et al.Leukemia Research|March 15, 2006
Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcomeYeon Hee Park, Won Seog Kim, Soo Mee Bang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancerKomal Jhaveri, Sherene Loi, Erika Hamilton, et al.Journal of the National Cancer Institute|June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 studyRebecca Dent, Javier Cortés, Lajos Pusztai, et al.Human Genetics|August 26, 2011
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populationsMyung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, et al.Breast Cancer (Tokyo, Japan)|June 17, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 studyToshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, et al.Cancer Discovery|October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup AnalysisGuy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.Breast Cancer (Tokyo, Japan)|January 23, 2023
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)Shigeru Imoto, Kun Wang, Xi-Wen Bi, et al.The New England Journal of Medicine|February 27, 2020
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Lajos Pusztai, et al.The Oncologist|June 6, 2023
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast CancerHan-Byoel Lee, Kyung-Hun Lee, Seok Hyun Song, et al.Pageof 37